The end of adjuvant chemotherapy (adCT) era with doxorubicin-based regimen in resected high-grade soft tissue sarcoma (STS): Pooled analysis of the two STBSG-EORTC phase III clinical trials

Authors:
  • ACA. Le Cesne
    A. Le Cesne
  • MGM. Van Glabbeke
    M. Van Glabbeke
  • PWP. J. Woll
    P. J. Woll
  • VBV. H. Bramwell
    V. H. Bramwell
  • PCP. G. Casali
    P. G. Casali
  • HHH. J. Hoekstra
    H. J. Hoekstra
  • PRP. Reichardt
    P. Reichardt
  • PHP. Hohenberger
    P. Hohenberger

Abstract
10525 Background: The EORTC STBSG has coordinated the two largest trials of adCT vs no adCT in localized high grade STS. In both studies adCT failed to demonstrate any benefit on overall survival (OS). The aim of this analysis was to identify subgroups of patients who benefit more from adjuvant CT than others. Methods: We pooled individual patient (pt) data from two EORTC trials comparing adCT (CYVADIC in 62771 and AI in 62931) to a control arm in completely resected STS (R0 or R1) to identify prognostic factors, by univariate and a multivariate analysis. The outcome of pts (OS or PFS) was subsequently compared between the two groups of pts according to each investigated factor. Results: A total of 819 pts were included, with a median follow-up of 8.2 years (62771 trial: 468 pts, 9.7 yrs; 62931 trial: 351 pts; 6.6 yrs). Large tumor size, high histologic grade and R1 resection are independent adverse prognostic factors for both PFS and OS. AdCT is an independent favourable prognostic factor for PFS but not...